Literature DB >> 9892213

Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases.

E Putz1, K Witter, S Offner, P Stosiek, A Zippelius, J Johnson, R Zahn, G Riethmüller, K Pantel.   

Abstract

Bone marrow (BM) is a clinically relevant site of micrometastatic disease in patients with solid epithelial tumors. It is, therefore, important to establish suitable models that allow the in-depth characterization of disseminated tumor cells present at low frequencies of 10(-5)-10(-6) nucleated BM cells. The aim of this study was to assess common phenotypic features of nine tumor cell lines established from BM of patients with cancer of the prostate (four cell lines), breast (two cell lines), lung (two cell lines), and colon (one cell line) using immunocytochemistry, flow cytometry, and reverse transcription-PCR. All cell lines stained positive for both cytokeratins, the epithelial intermediate filaments, and the epithelial cell adhesion molecule E-cadherin, and they lacked markers of BM-derived cells. The tumor origin of the cell lines was supported by the expression of the ErbB2 oncogene (seven of nine) and MAGE mRNA (eight of eight). All cell lines coexpressed cytokeratin and vimentin, the mesenchymal intermediate filament, indicating an epithelial-mesenchymal transition of micrometastatic cells. The invasive phenotype of the immortalized cells was also reflected by the consistent expression of several metastasis-associated adhesion molecules, including alpha5 (eight of nine), alpha6 (five of nine), alphaV (nine of nine), beta1 (nine of nine), and beta3 (nine of nine) integrin subunits and the Mr 67,000 laminin receptor (seven of nine). Contrary to our expectations, metastasis-promoting CD44 variant isoforms were only detected on two lines, whereas all cell lines expressed MUC18/melanoma cell adhesion molecule and intercellular adhesion molecule-1, two members of the immunoglobulin superfamily of adhesion molecules that are not frequently found on primary carcinoma cells. The consistent expression of various epithelial and tumor-associated antigens provides evidence that the established cell lines are derived from disseminated cancer cells present in the BM. The invasive phenotype of the immortalized cells was mirrored by their epithelial-mesenchymal transition and the expression of several metastasis-associated molecules, which might be potential candidates for novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892213

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Differential regulation of a novel variant of the alpha(6) integrin, alpha(6p).

Authors:  Tracy L Davis; Friederike Buerger; Anne E Cress
Journal:  Cell Growth Differ       Date:  2002-03

Review 2.  The role of alpha(v)beta(3) in prostate cancer progression.

Authors:  Carlton R Cooper; Christopher H Chay; Kenneth J Pienta
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

3.  Identification of a novel structural variant of the alpha 6 integrin.

Authors:  T L Davis; I Rabinovitz; B W Futscher; M Schnölzer; F Burger; Y Liu; M Kulesz-Martin; A E Cress
Journal:  J Biol Chem       Date:  2001-05-18       Impact factor: 5.157

4.  beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium.

Authors:  Valerie M Weaver; Sophie Lelièvre; Johnathon N Lakins; Micah A Chrenek; Jonathan C R Jones; Filippo Giancotti; Zena Werb; Mina J Bissell
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

5.  Synthetic D-amino acid peptide inhibits tumor cell motility on laminin-5.

Authors:  Thomas C Sroka; Michael E Pennington; Anne E Cress
Journal:  Carcinogenesis       Date:  2006-03-14       Impact factor: 4.944

6.  Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.

Authors:  Ajjai Alva; Susan Slovin; Stephanie Daignault; Michael Carducci; Robert Dipaola; Ken Pienta; David Agus; Kathleen Cooney; Alice Chen; David C Smith; Maha Hussain
Journal:  Invest New Drugs       Date:  2010-11-04       Impact factor: 3.850

7.  Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.

Authors:  Apollo D Kacsinta; Cynthia S Rubenstein; Isis C Sroka; Sangita Pawar; Jaime M Gard; Raymond B Nagle; Anne E Cress
Journal:  Biochem Biophys Res Commun       Date:  2014-10-22       Impact factor: 3.575

8.  Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression.

Authors:  Rong Shao; Shideng Bao; Xuefang Bai; Carrie Blanchette; Ryan M Anderson; Tongyun Dang; Mikhail L Gishizky; Jeffrey R Marks; Xiao-Fan Wang
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

9.  Mesenchymal migration as a therapeutic target in glioblastoma.

Authors:  Jessie Zhong; Andre Paul; Stewart J Kellie; Geraldine M O'Neill
Journal:  J Oncol       Date:  2010-06-21       Impact factor: 4.375

10.  Differential baseline and response profile to IFN-gamma gene transduction of IL-6/IL-6 receptor-alpha secretion discriminate primary tumors versus bone marrow metastases of nasopharyngeal carcinomas in culture.

Authors:  Andy Shau-Bin Chou; Hsin-Yi Wang; Hung-Chang Chen; Ming-Hsiu Tsai; Cheng-Keng Chuang; Shuen-Kuei Liao
Journal:  BMC Cancer       Date:  2009-06-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.